PROMISE-meso:帕博利珠单抗对比单药化疗治疗复发恶性胸膜间皮瘤的III期随机试验
PROMISE-meso是一项开放标签1:1随机III期试验,入组144例铂类化疗后进展的恶性胸膜间皮瘤患者,比较帕博利珠单抗(200 mg/Q3W)与研究者选择的单药化疗(吉西他滨或长春瑞滨)。主要终点BICR评估的PFS无差异(HR=1.06,95%CI 0.73-1.53,P=0.76),帕博利珠单抗ORR更高(22% vs 6%,P=0.004),但OS无差异(HR=1.12,95%CI 0.74-1.69,P=0.59)。
要点
- 帕博利珠单抗未改善BICR-PFS或OS,不优于单药化疗。
- 帕博利珠单抗ORR显著更高(22% vs 6%,P=0.004)。
- PD-L1状态探索性分析未显示ORR/PFS/OS获益。
核心结论
- 在未选择生物标志物的复发MPM患者中,帕博利珠单抗虽提高ORR,但未改善PFS或OS,不优于单药化疗。
研究设计与样本
- 开放标签1:1随机III期试验,入组144例铂类化疗后进展的MPM患者,PS 0-1,未选择PD-L1状态。
- 帕博利珠单抗200 mg/Q3W对比研究者选择的单药化疗(吉西他滨或长春瑞滨)。
- 主要终点为BICR评估的PFS;化疗组进展后允许交叉至帕博利珠单抗。
主要发现
- BICR-PFS无差异(HR=1.06,95%CI 0.73-1.53,P=0.76),中位BICR-PFS帕博利珠单抗2.5个月(95%CI 2.1-4.2)vs 化疗3.4个月(95%CI 2.2-4.3)。
- ORR帕博利珠单抗22%(95%CI 13%-33%)vs 化疗6%(95%CI 2%-14%),P=0.004。
- OS无差异(HR=1.12,95%CI 0.74-1.69,P=0.59),交叉调整后仍无差异。
- PD-L1状态探索性分析未显示ORR/PFS/OS改善。
关键数值与推荐
- 帕博利珠单抗200 mg/Q3W;单药化疗为吉西他滨或长春瑞滨(机构选择)。
- 主要终点BICR-PFS:HR=1.06,95%CI 0.73-1.53,P=0.76。
- ORR:帕博利珠单抗22%(95%CI 13%-33%)vs 化疗6%(95%CI 2%-14%),P=0.004。
- OS:HR=1.12,95%CI 0.74-1.69,P=0.59。
临床怎么用
- 对于铂类化疗后进展的MPM,帕博利珠单抗单药不作为优于单药化疗的常规选择。
- 帕博利珠单抗安全性与此前观察一致。
- PD-L1状态未显示可预测获益,不支持据此选择患者。
局限性
- 化疗组允许交叉至帕博利珠单抗,可能影响OS解读。
- PD-L1分析为探索性。
- 样本量144例,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterised by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trials of immune-checkpoint inhibitors have demonstrated encouraging activity. PATIENTS AND METHODS: PROMISE-meso is an open-label 1:1 randomised phase III trial investigating the efficacy of pembrolizumab (200 mg/Q3W) versus institutional choice single-agent chemotherapy (gemcitabine or vinorelbine) in relapsed MPM patients with progression after/on previous platinum-based chemotherapy. Patients were performance status 0-1 and unselected for programmed cell death ligand 1 (PD-L1) status. At progression, patients randomly assigned to receive chemotherapy were allowed to crossover to pembrolizumab. The primary end point was progression-free survival (PFS), assessed by blinded independent central review (BICR). Secondary end points were overall survival (OS), investigator-assessed PFS, objective response rate (ORR), and safety. Efficacy by PD-L1 status was investigated in exploratory analyses. RESULTS: Between September 2017 and August 2018, 144 patients were randomly allocated (pembrolizumab: 73; chemotherapy: 71). At data cut-off [20 February 2019, median follow-up of 11.8 months (interquartile range: 9.9-14.5)], 118 BICR-PFS events were observed. No difference in BICR-PFS was detected [hazard ratio = 1.06, 95% confidence interval (CI): 0.73-1.53; P = 0.76], and median BICR-PFS (95% CI) for pembrolizumab was 2.5 (2.1-4.2), compared with 3.4 (2.2-4.3) months for chemotherapy. A difference in ORR for pembrolizumab was identified (22%, 95% CI: 13% to 33%), over chemotherapy (6%, 95% CI: 2% to 14%; P = 0.004). Forty-five patients (63%) assigned to chemotherapy received pembrolizumab at progression. With follow-up to 21 August 2019 [17.5 months: (14.8-19.7)], no difference in OS was detected between groups (HR = 1.12, 95% CI: 0.74-1.69; P = 0.59), even after adjusting for crossover. Pembrolizumab safety was consistent with previous observations. Exploratory efficacy analyses by PD-L1 status demonstrated no improvements in ORR/PFS/OS. CONCLUSION: This is the first randomised trial evaluating the efficacy of pembrolizumab in MPM patients progressing after/on previous platinum-based chemotherapy. In biologically unselected patients, although associated with an improved ORR, pembrolizumab improves neither PFS nor OS over single-agent chemotherapy.
引用
- Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2020. PMID: 32976938. doi:10.1016/j.annonc.2020.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。